Relay kicks off public offering, seeking $300M after laying out robust ESMO data
Four days after joining the proverbial winner’s circle thanks to its bile duct cancer drug candidate, Relay Therapeutics is upping the ante and looking to up its coffers by a few hundred million for its next steps.
The company reported bright and early Monday morning that it was commencing a public offering to the tune of $300 million. While details are few and far between, the biotech said underwriters get 30 days to purchase another 15% of the shares offered in the public offering — which according to market conditions could be in the $45 million range.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.